We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Targeting Diseased Areas using Enzyme-Sensitive Contrast Agents for MRI

By MedImaging staff writers
Posted on 16 Jun 2008
Magnetic resonance imaging (MRI) has become a standard modality in clinical diagnosis due to the use of contrast agents, which enable the contrast between healthy tissue and diseased tissue to be increased. More...
However, the agents currently used clinically do not allow the identification of particular pathologies or of the affected area of the body. The recent work of two French teams has brought hope in this area.

The recent research of two CNRS (Centre National de la Recherche Scientifique; Vandoeuvre-lès-Nancy [near Nancy], France) teams from Orleans and Gif-sur-Yvette (Orleans' Centre de Biophysique Moléculaire and the Institut de Chimie des Substances Naturelles in Gif-sur-Yvette [near Paris]) have demonstrated that by using a new class of contrast agents sensitive to enzymes, it is possible to locate the affected part of the body. The molecules act as switches--when they encounter a specific enzyme, this initiates a cascade reaction, leading to the activation of the contrast agent, which then becomes detectable in an MRI image. The systems have two positions--they are "off” in the absence of the enzyme, and "on” if present. Therefore, an image is only received when the contrast agents are activated.

The reactions caused by certain enzymes may be an indication of the state of the cells, and be interpreted as the signature of a given disease process. In the future, detection of enzymes due to these contrast agents should enable clinicians to diagnose a disease with a simple MRI examination. Moreover, the system can be modulated and is potentially applicable to a large variety of enzymes, and, therefore, pathologies.

Understanding the mechanism of these new molecules for medical imaging constitutes a major advance in visualizing molecular processes in vivo, as well as in detecting pathologies.

Founded in 1939 by French governmental decree, CNRS' goals include: to evaluate and carry out all research capable of advancing knowledge and bringing social, cultural, and economic benefits for society; contribute to the application and promotion of research results; develop scientific information and support research training; and participate in the analysis of the national and international scientific climate and its potential for evolution to develop a national policy.


Related Links:
CNRS

Gold Member
12-Channel ECG
CM1200B
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Syringe Pump
SP50 Series
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Aliya EX Generator for surgical ablation of soft tissue (Photo courtesy of Galvanize Therapeutics)

Next-Generation PEF System Delivers Larger Ablation Zones for Soft-Tissue Procedures

Interventional teams often need soft-tissue ablation options that can be performed percutaneously or endoscopically while minimizing collateral injury and preserving procedural workflow.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.